STICHTING EUROPEAN UROLOGICAL FOUNDATION

Their core work

The European Urological Foundation (EAU) is the research and education arm of the European Association of Urology, Europe's leading professional body for urological medicine. Their core work involves coordinating large-scale, multi-country clinical research programmes that translate real-world patient data into evidence-based treatment guidelines used by urologists across Europe. In H2020, they have focused specifically on harnessing big data, genetic profiling, and artificial intelligence to close critical evidence gaps in cancer diagnosis and treatment — particularly prostate cancer and solid tumours. Their role is not laboratory research but clinical research orchestration: assembling multi-disciplinary consortia, defining research priorities, and ensuring findings feed directly into clinical practice.

What they specialise in

How they've shifted over time

EAU's first H2020 project (PIONEER, 2018) focused on mapping what was unknown — identifying evidence gaps, establishing natural history baselines, and building multi-source data infrastructure for prostate cancer using genetic profiles and pilot datasets. By 2021, with OPTIMA, the emphasis had shifted decisively from data collection to data application: big data analysis, real-world evidence, and artificial intelligence now drive the work. This reflects a natural maturation — having built the evidence base, EAU is now using it to generate AI-powered treatment recommendations and codify findings into guidelines.

EAU is moving from research infrastructure builder toward AI-in-medicine applicator — future projects will likely involve deploying AI decision-support tools directly into clinical urology practice across Europe.

How they like to work

EAU consistently takes the coordinator role — they have never appeared as a participant or third party in H2020, which signals an organisation that drives research agendas rather than joining others' programmes. Despite coordinating only two projects, they have assembled unusually large consortia: 61 unique partners across 17 countries, averaging over 30 partners per project. This suggests a hub model where EAU provides clinical legitimacy, guideline authority, and pan-European network access, while technical and data partners deliver execution.

EAU's network spans 61 partners across 17 countries, a broad reach for just two projects, reflecting their position as a pan-European clinical authority with deep connections to hospitals, cancer registries, and research institutions across the continent. No single geographic cluster is dominant — their network is genuinely European rather than regionally concentrated.

What sets them apart

EAU brings something few academic or technical partners can offer: institutional authority over European urology clinical guidelines, meaning their research outputs have a direct, credible pathway into standard medical practice across EU member states. For any consortium working on oncology data, diagnostics, or AI in cancer care, EAU provides not just clinical expertise but the professional network and guideline infrastructure to ensure research actually changes how doctors treat patients. A consortium with EAU as coordinator signals to reviewers that findings will be adopted — not just published.

Highlights from their portfolio

• PIONEER
  One of the first large-scale European big data initiatives in prostate cancer, PIONEER built multi-source data infrastructure linking genetic profiles, natural history data, and real-world pilot cases across multiple countries.
• OPTIMA
  With the highest EC contribution (€822,280) and a 2021-2026 timeline, OPTIMA is EAU's most ambitious project — applying AI to optimise treatment decisions for solid tumour patients across Europe and directly feeding outputs into clinical guidelines.